{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:44:26Z","timestamp":1785300266088,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1245\/s10434-024-16621-x","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:47:11Z","timestamp":1733842031000},"page":"3568-3577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Survival of Patients with Resected Microsatellite Instability-High, Mismatch Repair Deficient, and Lynch Syndrome-Associated Pancreatic Ductal Adenocarcinomas"],"prefix":"10.1245","volume":"32","author":[{"given":"Ellis L.","family":"Eikenboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naaz","family":"Nasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Seier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon C. W.","family":"Spaander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Drebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Peter","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-959X","authenticated-orcid":false,"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"16621_CR1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"16621_CR2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1245\/s10434-014-4196-2","volume":"22","author":"PE Serrano","year":"2015","unstructured":"Serrano PE, Cleary SP, Dhani N, et al. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods. Ann Surg Oncol. 2015;22:1160\u20137.","journal-title":"Ann Surg Oncol."},{"key":"16621_CR3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology, and clinical implications. Gut. 2021;70:148\u201356.","journal-title":"Gut."},{"key":"16621_CR4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/j.gastro.2017.11.009","volume":"154","author":"RM Lupinacci","year":"2018","unstructured":"Lupinacci RM, Goloudina A, Buhard O, et al. Prevalence of microsatellite instability in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2018;154:1061\u20135.","journal-title":"Gastroenterology"},{"key":"16621_CR5","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/cncr.33038","volume":"126","author":"CA McIntyre","year":"2020","unstructured":"McIntyre CA, Lawrence SA, Richards AL, et al. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. 2020;126:3939\u201349.","journal-title":"Cancer."},{"key":"16621_CR6","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1245\/s10434-019-08096-y","volume":"27","author":"JE Ordonez","year":"2020","unstructured":"Ordonez JE, Hester CA, Zhu H, et al. Clinicopathologic features and outcomes of early-onset pancreatic adenocarcinoma in the United States. Ann Surg Oncol. 2020;27:1997\u20132006.","journal-title":"Ann Surg Oncol."},{"key":"16621_CR7","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, George B, Greenbowe JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156:2242\u201353.","journal-title":"Gastroenterology."},{"key":"16621_CR8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/368258a0","volume":"368","author":"CE Bronner","year":"1994","unstructured":"Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994;368:258\u201361.","journal-title":"Nature."},{"key":"16621_CR9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(93)90546-3","volume":"75","author":"R Fishel","year":"1993","unstructured":"Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027\u201338.","journal-title":"Cell."},{"key":"16621_CR10","first-page":"3920","volume":"57","author":"Y Akiyama","year":"1997","unstructured":"Akiyama Y, Sato H, Yamada T, et al. Germ-line mutation of the hMSH6\/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 1997;57:3920\u20133.","journal-title":"Cancer Res."},{"key":"16621_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/371075a0","volume":"371","author":"NC Nicolaides","year":"1994","unstructured":"Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371:75\u201380.","journal-title":"Nature."},{"key":"16621_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ng.283","volume":"41","author":"MJ Ligtenberg","year":"2009","unstructured":"Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3\u2019 exons of TACSTD1. Nature Genet. 2009;41:112\u20137. https:\/\/doi.org\/10.1038\/ng.283.","journal-title":"Nature Genet."},{"key":"16621_CR13","volume":"13","author":"S Han","year":"2022","unstructured":"Han S, Chok AY, Peh DYY, et al. The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers. Front Genet. 2022;13:933475.","journal-title":"Front Genet."},{"key":"16621_CR14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1053\/j.gastro.2013.12.002","volume":"146","author":"AR Mensenkamp","year":"2014","unstructured":"Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146:643\u20136.","journal-title":"Gastroenterology."},{"key":"16621_CR15","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2009.1529","volume":"302","author":"F Kastrinos","year":"2009","unstructured":"Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302:1790\u20135.","journal-title":"JAMA."},{"key":"16621_CR16","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P M\u00f8ller","year":"2018","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67:1306\u201316.","journal-title":"Gut."},{"key":"16621_CR17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med."},{"key":"16621_CR18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability-high or mismatch repair-deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929\u201338.","journal-title":"Ann Oncol."},{"key":"16621_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol."},{"key":"16621_CR20","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Bucheit L, Starr JS, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022;10:e004485.","DOI":"10.1136\/jitc-2021-004485"},{"key":"16621_CR21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148:556\u201364.","journal-title":"Gastroenterology."},{"key":"16621_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.Ccr-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24:1326\u201336. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3099.","journal-title":"Clin Cancer Res."},{"key":"16621_CR23","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073\u201387.","journal-title":"Gastroenterology."},{"key":"16621_CR24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/gutjnl-2020-320730","volume":"70","author":"RC Grant","year":"2021","unstructured":"Grant RC, Denroche R, Jang GH, et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Gut. 2021;70:1894\u2013903.","journal-title":"Gut."},{"key":"16621_CR25","first-page":"3139","volume":"61","author":"H Yamamoto","year":"2001","unstructured":"Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 2001;61:3139\u201344.","journal-title":"Cancer Res."},{"key":"16621_CR26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.03.033","volume":"169","author":"E Karamitopoulou","year":"2022","unstructured":"Karamitopoulou E, Andreou A, Wenning AS, Gloor B, Perren A. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Eur J Cancer. 2022;169:64\u201373.","journal-title":"Eur J Cancer."},{"key":"16621_CR27","doi-asserted-by":"crossref","first-page":"1123901","DOI":"10.3389\/fonc.2023.1123901","volume":"13","author":"K Zalevskaja","year":"2023","unstructured":"Zalevskaja K, Mecklin JP, Sepp\u00e4l\u00e4 TT. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: a retrospective analysis from the Finnish National Lynch Syndrome Research Registry. Front Oncol. 2023;13:1123901.","journal-title":"Front Oncol."},{"key":"16621_CR28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251\u201364.","journal-title":"J Mol Diagn."},{"issue":"D1","key":"16621_CR29","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062\u20137.","journal-title":"Nucleic Acids Res."},{"key":"16621_CR30","doi-asserted-by":"publisher","unstructured":"Middha S, Zhang L, Nafa K, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00084.","DOI":"10.1200\/PO.17.00084"},{"key":"16621_CR31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015\u20136.","journal-title":"Bioinformatics."},{"key":"16621_CR32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov."},{"key":"16621_CR33","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal."},{"key":"16621_CR34","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. 2021. https:\/\/www.R-project.org\/."},{"key":"16621_CR35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/SLA.0000000000006142","volume":"280","author":"IF Rompen","year":"2024","unstructured":"Rompen IF, Levine J, Habib JR, et al. Progression of site-specific recurrence of pancreatic cancer and implications for treatment. Ann Surg. 2024;280:317\u201324.","journal-title":"Ann Surg."},{"key":"16621_CR36","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.14309\/ajg.0000000000002314","volume":"118","author":"I Shah","year":"2023","unstructured":"Shah I, Silva-Santisteban A, Germansky KA, et al. Pancreatic cancer screening for at-risk individuals (Pancreas Scan Study): yield, harms, and outcomes from a prospective multicenter study. Am J Gastroenterol. 2023;118:1664\u201370.","journal-title":"Am J Gastroenterol."},{"key":"16621_CR37","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/jcm9072132","volume":"9","author":"B Ratnayake","year":"2020","unstructured":"Ratnayake B, Savastyuk AY, Nayar M, et al. Recurrence patterns for pancreatic ductal adenocarcinoma after upfront resection versus resection following neoadjuvant therapy: a comprehensive meta-analysis. J Clin Med. 2020;9:2132.","journal-title":"J Clin Med."},{"key":"16621_CR38","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s00262-023-03397-4","volume":"72","author":"MH Storandt","year":"2023","unstructured":"Storandt MH, Tran N, Martin N, Jatoi A. Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden. Cancer Immunol Immunother. 2023;72:2515\u201320.","journal-title":"Cancer Immunol Immunother."},{"key":"16621_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13046-020-01732-6","volume":"39","author":"C Luchini","year":"2020","unstructured":"Luchini C, Paolino G, Mattiolo P, et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39:227.","journal-title":"J Exp Clin Cancer Res."},{"key":"16621_CR40","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell. 2024;42:1614\u201329.","journal-title":"Cancer Cell."},{"key":"16621_CR41","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/gut.2005.083063","volume":"55","author":"J Kim","year":"2006","unstructured":"Kim J, Reber HA, Dry SM, et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut. 2006;55:1598\u2013605.","journal-title":"Gut."},{"key":"16621_CR42","doi-asserted-by":"crossref","first-page":"458","DOI":"10.21037\/jgo-22-587","volume":"14","author":"MY Han","year":"2023","unstructured":"Han MY, Borazanci E. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report. J Gastrointest Oncol. 2023;14:458\u201362.","journal-title":"J Gastrointest Oncol."},{"key":"16621_CR43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.6004\/jnccn.2021.7049","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang Y, Cuggia A, Pacis A, et al. Pancreatic cancer progression in a patient with lynch syndrome receiving immunotherapy: a cautionary tale. J Natl Compr Cancer Netw. 2021;19:883\u20137.","journal-title":"J Natl Compr Cancer Netw."},{"key":"16621_CR44","volume":"36","author":"AS van der Werf-'t Lam","year":"2023","unstructured":"van der Werf-\u2019t Lam AS, Terlouw D, Tops CM, et al. Discordant staining patterns and microsatellite results in tumors of MSH6 pathogenic variant carriers. Mod Pathol. 2023;36:100240.","journal-title":"Mod Pathol."},{"key":"16621_CR45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000274","volume":"6","author":"AE Hendifar","year":"2019","unstructured":"Hendifar AE, Larson BK, Rojansky R, et al. Pancreatic cancer \u201cmismatch\u201d in Lynch syndrome. BMJ Open Gastroenterol. 2019;6:e000274.","journal-title":"BMJ Open Gastroenterol."},{"key":"16621_CR46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","volume":"37","author":"A Latham","year":"2019","unstructured":"Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J Clin Oncol. 2019;37:286\u201395.","journal-title":"J Clin Oncol."},{"key":"16621_CR47","volume":"216","author":"SA Ahmad-Nielsen","year":"2020","unstructured":"Ahmad-Nielsen SA, Bruun Nielsen MF, Mortensen MB, Detlefsen S. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Pathol Res Pract. 2020;216:152985.","journal-title":"Pathol Res Pract."},{"key":"16621_CR48","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2016-311403","volume":"66","author":"P M\u00f8ller","year":"2017","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut. 2017;66:1657\u201364.","journal-title":"Gut."},{"key":"16621_CR49","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cgh.2019.08.043","volume":"18","author":"A Goverde","year":"2020","unstructured":"Goverde A, Eikenboom EL, Viskil EL, et al. Yield of lynch syndrome surveillance for patients with pathogenic variants in DNA mismatch repair genes. Clin Gastroenterol Hepatol. 2020;18:1112\u201320.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"16621_CR50","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.gim.2022.02.016","volume":"24","author":"YL Liu","year":"2022","unstructured":"Liu YL, Cadoo KA, Maio A, et al. Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genet Med. 2022;24:1187\u201395.","journal-title":"Genet Med."},{"key":"16621_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.gastro.2016.09.060","volume":"152","author":"JL Humphris","year":"2017","unstructured":"Humphris JL, Patch AM, Nones K, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152:68\u201374. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.060.","journal-title":"Gastroenterology."},{"key":"16621_CR52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jhep.2022.09.025","volume":"78","author":"Y Okawa","year":"2023","unstructured":"Okawa Y, Iwasaki Y, Johnson TA, et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol. 2023;78:333\u201342.","journal-title":"J Hepatol."},{"key":"16621_CR53","first-page":"5571","volume":"11","author":"H Liao","year":"2021","unstructured":"Liao H, Cai S, Bai Y, et al. Prevalence and spectrum of germline cancer susceptibility gene variants and somatic second hits in colorectal cancer. Am J Cancer Res. 2021;11:5571\u201380.","journal-title":"Am J Cancer Res."},{"key":"16621_CR54","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.22.00194","volume":"40","author":"DCF Klatte","year":"2022","unstructured":"Klatte DCF, Boekestijn B, Wasser M, et al. Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-year prospective follow-up. J Clin Oncol. 2022;40:3267\u201377.","journal-title":"J Clin Oncol."},{"key":"16621_CR55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.gastro.2020.03.088","volume":"159","author":"HR Aslanian","year":"2020","unstructured":"Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159:358\u201362.","journal-title":"Gastroenterology."},{"key":"16621_CR56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69:7\u201317.","journal-title":"Gut."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16621-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16621-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16621-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T06:20:06Z","timestamp":1744093206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16621-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["16621"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16621-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eileen M. O\u2019Reilly reports research funding to Genentech\/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH\/NCI, and Digestive Care, Break Through Cancer, as well as consulting\/DSMB for Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus Agios (spouse), Genentech-Roche (spouse), Eisai (spouse), Servier (spouse). Jeffrey Drebin reports employment and leadership at American Regent (spouse) and stock and other ownership interests in Alnylam, Arrowhead Pharmaceuticals and Ions pharmaceuticals. Vinod P. Balachandran reports research funding from Genetech\/Roche and was an inventor on patent applications related to antigen cross-reactivity and neoantigen quality modeling. Alice C. Wei reports consulting for Histosonics and clinical trial funding from Ipsen. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}